Tarsus Pharmaceuticals, Inc. (TARS)
NASDAQ: TARS · Real-Time Price · USD
49.98
-1.76 (-3.40%)
Mar 31, 2025, 1:22 PM EDT - Market open
Tarsus Pharmaceuticals Stock Forecast
Stock Price Forecast
The 6 analysts with 12-month price forecasts for Tarsus Pharmaceuticals stock have an average target of 63.67, with a low estimate of 41 and a high estimate of 78. The average target predicts an increase of 27.39% from the current stock price of 49.98.
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Tarsus Pharmaceuticals stock from 6 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Oct '24 | Nov '24 | Dec '24 | Jan '25 | Feb '25 | Mar '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 3 | 2 | 2 | 2 | 3 | 3 |
| Buy | 2 | 2 | 2 | 2 | 2 | 2 |
| Hold | 1 | 1 | 1 | 1 | 1 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 6 | 5 | 5 | 5 | 6 | 6 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Jefferies | Jefferies | Strong Buy Maintains $54 → $58 | Strong Buy | Maintains | $54 → $58 | +16.05% | Mar 6, 2025 |
| Guggenheim | Guggenheim | Strong Buy Maintains $75 → $78 | Strong Buy | Maintains | $75 → $78 | +56.06% | Feb 26, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $73 | Strong Buy | Reiterates | $73 | +46.06% | Feb 26, 2025 |
| Barclays | Barclays | Buy Maintains $62 → $60 | Buy | Maintains | $62 → $60 | +20.05% | Feb 26, 2025 |
| Guggenheim | Guggenheim | Strong Buy Reiterates n/a | Strong Buy | Reiterates | n/a | n/a | Feb 24, 2025 |
Financial Forecast
Revenue This Year
349.32M
from 182.95M
Increased by 90.93%
Revenue Next Year
510.14M
from 349.32M
Increased by 46.04%
EPS This Year
-1.80
from -3.07
EPS Next Year
1.12
from -1.80
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 392.4M | 576.5M | 792.8M | ||
| Avg | 349.3M | 510.1M | 688.4M | ||
| Low | 301.8M | 408.7M | 525.3M |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 114.5% | 65.0% | 55.4% | ||
| Avg | 90.9% | 46.0% | 34.9% | ||
| Low | 65.0% | 17.0% | 3.0% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | -1.23 | 1.72 | 6.96 | ||
| Avg | -1.80 | 1.12 | 3.68 | ||
| Low | -2.35 | 0.29 | 1.16 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | 519.3% | ||
| Avg | - | - | 227.1% | ||
| Low | - | - | 2.9% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.